Sofosbuvir/velpatasvir/voxilaprevir

Sofosbuvir/velpatasvir/voxilaprevir
Combination of
SofosbuvirNS5B RNA polymerase inhibitor
VelpatasvirNS5A inhibitor
VoxilaprevirNS3/4A protease inhibitor
Names
Trade namesVosevi
Clinical data
Main usesHepatitis C[1]
Side effectsHeadache, tiredness, diarrhea, trouble sleeping, nausea[2]
WHO AWaReUnlinkedWikibase error: ⧼unlinkedwikibase-error-statements-entity-not-set⧽
Pregnancy
category
  • AU: B1
  • US: N (Not classified yet)
    Routes of
    use    		By mouth (tablets)
    External links
    AHFS/Drugs.comMonograph
    MedlinePlusa617037
    Legal
    License data
    Legal status
    • AU: S4 (Prescription only)
    • US: ℞-only
    • EU: Rx-only
    Chemical and physical data
    FormulaC111H135F5N17O26PS
    Molar mass2281.42 g·mol−1
    3D model (JSmol)
    SMILES
    • CCC1C2CN(C1C(=O)NC3(CC3C(F)F)C(=O)NS(=O)(=O)C4(CC4)C)C(=O)C(NC(=O)OC5CC5CCCCC(C6=NC7=C(C=C(C=C7)OC)N=C6O2)(F)F)C(C)(C)C.CC1CCC(N1C(=O)C(C(C)C)NC(=O)OC)C2=NC3=C(N2)C=CC4=CC5=C(C=C43)OCC6=C5C=CC(=C6)C7=CN=C(N7)C8CC(CN8C(=O)C(C9=CC=CC=C9)NC(=O)OC)COC.CC(C)OC(=O)C(C)NP(=O)(OCC1C(C(C(O1)N2C=CC(=O)NC2=O)(C)F)O)OC3=CC=CC=C3
    InChI
    • InChI=1S/C49H54N8O8.C40H52F4N6O9S.C22H29FN3O9P/c1-26(2)41(54-48(60)63-5)47(59)57-27(3)12-17-38(57)45-51-36-16-14-30-20-35-33-15-13-31(19-32(33)25-65-40(35)21-34(30)43(36)53-45)37-22-50-44(52-37)39-18-28(24-62-4)23-56(39)46(58)42(55-49(61)64-6)29-10-8-7-9-11-29;1-7-22-27-19-50(28(22)32(51)48-39(18-23(39)31(41)42)35(53)49-60(55,56)38(5)14-15-38)34(52)30(37(2,3)4)47-36(54)59-26-16-20(26)10-8-9-13-40(43,44)29-33(58-27)46-25-17-21(57-6)11-12-24(25)45-29;1-13(2)33-19(29)14(3)25-36(31,35-15-8-6-5-7-9-15)32-12-16-18(28)22(4,23)20(34-16)26-11-10-17(27)24-21(26)30/h7-11,13-16,19-22,26-28,38-39,41-42H,12,17-18,23-25H2,1-6H3,(H,50,52)(H,51,53)(H,54,60)(H,55,61);11-12,17,20,22-23,26-28,30-31H,7-10,13-16,18-19H2,1-6H3,(H,47,54)(H,48,51)(H,49,53);5-11,13-14,16,18,20,28H,12H2,1-4H3,(H,25,31)(H,24,27,30)/t27-,28-,38-,39-,41-,42+;20-,22-,23+,26-,27+,28+,30-,39-;14-,16+,18+,20+,22+,36-/m010/s1
    • Key:FMWRYUBVSONSCK-ZYTFCPLVSA-N

    Sofosbuvir/velpatasvir/voxilaprevir, sold under the brand name Vosevi, is a combination medication used to treat hepatitis C.[1] It is taken by mouth with food.[1] Effectiveness is greater than 95%.[1]

    Common side effects include headache, tiredness, diarrhea, trouble sleeping, and nausea.[2] Other side effects may include hepatitis B reactivation and liver problems.[2] While there is no clear evidence of harm during pregnancy, it has not been well studied in this group.[3] It contains sofosbuvir, velpatasvir, and voxilaprevir, each of which blocks an enzyme required by the virus.[1]

    The combination was approved for medical use in the United States and Europe in 2017.[1][2] In the United States 8 weeks of treatment costs about 48,500 USD as of 2021.[4] This amount in the United Kingdom costs the NHS about £30,000.[5]

    Medical uses

    It is used to treat hepatitis C.[1] It can be used for genotype 1 to 6.[5]

    Dosage

    It is typically take at a dose of one tablet a day for 8 to 12 weeks.[1]

    Each tablet contains 400 mg sofosbuvir, 100 mg velpatasvir, and 100 mg voxilaprevir.[1]

    Interactions

    It should not be used together with certain medicines including:[1]

    Society and culture

    Vosevi is sold by Gilead Sciences.[6]

    References

    1. 1 2 3 4 5 6 7 8 9 10 "Vosevi EPAR". European Medicines Agency (EMA). Archived from the original on 23 October 2020. Retrieved 24 September 2020.
    2. 1 2 3 4 "Sofosbuvir, Velpatasvir, And Voxilaprevir Monograph for Professionals". Drugs.com. Archived from the original on 12 January 2020. Retrieved 14 October 2021.
    3. ↑ "Sofosbuvir / velpatasvir / voxilaprevir (Vosevi) Use During Pregnancy". Drugs.com. Archived from the original on 28 November 2020. Retrieved 14 October 2021.
    4. ↑ "Vosevi Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 14 October 2021.
    5. 1 2 BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 667. ISBN 978-0-85711-369-6.
    6. ↑ "FDA approves Vosevi for Hepatitis C". U.S. Food and Drug Administration (FDA) (Press release). 18 July 2017. Archived from the original on 23 July 2017. Retrieved 27 July 2017.
    Identifiers:
    This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.